Stay updated with breaking news from Solara Active Pharma Sciences Ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Solara Active Pharma Sciences Ltd's Visakhapatnam facility receives positive USFDA inspection with zero observations, ensuring compliance and quality.
US Food and Drug Administration US FDA has successfully completed the inspection of the multipurpose API manufacturing facility of Solara Active Pharma Scienc
The US Food and Drug Administration (FDA) completes inspection of Solara Active Pharma Sciences' API manufacturing facility in Visakhapatnam, Andhra Pradesh, with no observations. Solara confirms compliance with FDA standards. The facility, dedicated to Ibuprofen API production, marks Solara's second successful FDA inspection. The company aims for global market expansion with FDA-approved facilities.
Most of these opt-outs have happened at firms plagued with governance issues
/PRNewswire/ -- The ibuprofen API market value is anticipated to grow by USD 31.68 million, progressing at a CAGR of 2.53% during the forecast period.The...